Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 601 - 625 of 10466 in total

Hexafluronium

Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases.
Approved
Matched Categories: … Cholinergic Agents ... Anticholinergic Agents ... Neurotransmitter Agents ... Muscle Relaxants, Peripherally Acting Agents …

Daptomycin

Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked...
Approved
Investigational
Matched Description: … acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ... [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name …
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... Agents Causing Muscle Toxicity …

Magnesium hydroxide

Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially...
Approved
Investigational
Matched Description: … Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable ... Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. …
Matched Categories: … Gastrointestinal Agents ... Gastric Acid Lowering Agents ... Agents that produce neuromuscular block (indirect) …

Flosequinan

Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Approved
Withdrawn
Matched Description: … Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due …
Matched Categories: … Cardiovascular Agents ... Vasodilating Agents …

Soybean oil

Derived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat. The...
Approved
Matched Description: … Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use. …
Matched Categories: … Caloric Agents …

Tixocortol

Tixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and toxicity.
Approved
Withdrawn
Matched Categories: … Anti-Allergic Agents ... Immunosuppressive Agents ... Intestinal Antiinflammatory Agents ... Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents …

Tepotinib

Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,[L31473] an ... In February 2022, tepotinib was approved for use in Europe.[L42200] ... Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Prednisone

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone was granted FDA approval on 21 February 1955.
Approved
Vet approved
Matched Categories: … Antineoplastic Agents ... Anti-Inflammatory Agents ... Immunosuppressive Agents ... Antineoplastic Agents, Hormonal ... Hyperglycemia-Associated Agents …

Resmetirom

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic …

Delandistrogene moxeparvovec

Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading...
Approved
Investigational
Matched Description: … Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta ... [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading ... Dystrophin is an essential protein responsible for muscle function; thus, patients with DMD experience …

Oxybutynin

Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for...
Approved
Investigational
Matched Description: … [A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used …
Matched Categories: … Autonomic Agents ... Anticholinergic Agents ... Urological Agents ... Genitourinary Agents ... Agents producing tachycardia …

Reslizumab

Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic ... Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous ... It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving …
Matched Categories: … Anti-Asthmatic Agents ... Respiratory System Agents …

Taliglucerase alfa

Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Matched Description: … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's …

Methionine

A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Approved
Nutraceutical

Methadone

Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a...
Approved
Matched Description: … and as an inhibitor of serotonin and norepinephrine uptake. ... agonist of κ- and σ-opioid receptors, as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, ... However, methadone also has an unpredictable half-life with interindividual variability, which leads …
Matched Categories: … Antidepressive Agents ... Antitussive Agents ... Anticholinergic Agents ... Serotonin Agents ... QTc Prolonging Agents …

Bexagliflozin

Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor.[A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is...
Approved
Investigational
Matched Description: … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with …
Matched Categories: … Blood Glucose Lowering Agents …

Elotuzumab

Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab...
Approved
Matched Description: … Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Diiodohydroxyquinoline

Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Description: … Iodoquinol is not currently available in any FDA-approved products. …
Matched Categories: … Anti-Infective Agents ... Antiparasitic Agents …

Drospirenone

Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with Ethinyl estradiol. Most recently, it was approved by both Health Canada and the FDA in combination with Estetrol as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to...
Approved
Matched Description: … ] as an oral contraceptive therapy. ... [L7973] Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol ... Drospirenone has been the subject of widespread safety concern due to the possibility of an increased …
Matched Categories: … Natriuretic Agents ... Agents causing hyperkalemia ... Contraceptive Agents, Female ... Hyperglycemia-Associated Agents …

Danaparoid

Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International ... Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting ... Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication …
Matched Categories: … Hematologic Agents ... Cardiovascular Agents ... Agents causing hyperkalemia ... Fibrin Modulating Agents …

Oxytetracycline

A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.
Approved
Investigational
Vet approved
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... Agents that produce neuromuscular block (indirect) …

Etonogestrel

Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
Approved
Investigational
Matched Description: … A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved …
Matched Categories: … Contraceptive Agents, Female ... Contraceptive Agents, Hormonal ... Reproductive Control Agents ... Hyperglycemia-Associated Agents …

Hexobendine

Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris. It has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany .
Approved
Matched Description: … It has not been approved in the United States or the United Kingdom, but has been used widely in Austria …
Matched Categories: … Cardiovascular Agents ... Vasodilating Agents …

Ferric maltol

Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Matched Description: … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability …
Matched Categories: … Hematologic Agents …

Ibandronate

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA...
Approved
Investigational
Matched Categories: … QTc Prolonging Agents ... Agents Causing Muscle Toxicity ... Bone Density Conservation Agents ... Potential QTc-Prolonging Agents …
Displaying drugs 601 - 625 of 10466 in total